managing relapsed all: the role of novel cellular therapies & importance of conditioning regimens
Published 5 months ago • 123 plays • Length 2:06Download video MP4
Download video MP3
Similar videos
-
1:46
optimizing conditioning regimens in patients with aml undergoing allosct
-
1:09
the changing role of allosct in dlbcl in the era of novel agents
-
1:13
selecting conditioning regimens for patients with myelofibrosis undergoing allosct
-
0:58
management strategies for acute and chronic gvhd following allosct
-
1:05
the importance of using mrd to guide treatment decisions in all
-
2:18
treating patients with advanced-stage hl in the frontline and relapsed settings in 2024
-
21:38
drawing the line: the rationale behind blood tube collection order
-
4:36
being marilyn…with myelofibrosis—an mf journey
-
4:36
living in the moment with myelofibrosis—david’s mf journey
-
2:45
safety and efficacy of inotuzumab ozogamicin conditioning for allosct in lymphoid malignancies
-
0:56
microbiota in hematologic malignancies
-
1:38
novel treatment options for lr-mds and the importance of clinical trials in this space
-
4:48
the evolution of allosct in richter's transformation and its combination with biological agents
-
8:33
boven regimen for previously untreated cll: long-term follow-up and mrd kinetics
-
2:09
advances in the management of fit adults with aml
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
3:07
the role of bridging and timing in car-t
-
4:43
how to manage relapsed/refractory mcl - new agents and unmet needs
-
1:01
advancements in cml: improving treatment-free remission and novel agents
-
2:02
recent advances in all treatment
-
2:09
heart transplantation in attr amyloidosis